Colon impairments and inflammation driven by an altered gut microbiota leads to social behavior deficits rescued by hyaluronic acid and celecoxib.


Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
29 Apr 2024
Historique:
received: 23 08 2023
accepted: 27 02 2024
medline: 30 4 2024
pubmed: 30 4 2024
entrez: 29 4 2024
Statut: epublish

Résumé

The exact mechanisms linking the gut microbiota and social behavior are still under investigation. We aimed to explore the role of the gut microbiota in shaping social behavior deficits using selectively bred mice possessing dominant (Dom) or submissive (Sub) behavior features. Sub mice exhibit asocial, depressive- and anxiety-like behaviors, as well as systemic inflammation, all of which are shaped by their impaired gut microbiota composition. An age-dependent comparative analysis of the gut microbiota composition of Dom and Sub mice was performed using 16S rRNA sequencing, from early infancy to adulthood. Dom and Sub gastrointestinal (GI) tract anatomy, function, and immune profiling analyses were performed using histology, RT-PCR, flow cytometry, cytokine array, and dextran-FITC permeability assays. Short chain fatty acids (SCFA) levels in the colons of Dom and Sub mice were quantified using targeted metabolomics. To support our findings, adult Sub mice were orally treated with hyaluronic acid (HA) (30 mg/kg) or with the non-steroidal anti-inflammatory agent celecoxib (16 mg/kg). We demonstrate that from early infancy the Sub mouse gut microbiota lacks essential bacteria for immune maturation, including Lactobacillus and Bifidobacterium genera. Furthermore, from birth, Sub mice possess a thicker colon mucin layer, and from early adulthood, they exhibit shorter colonic length, altered colon integrity with increased gut permeability, reduced SCFA levels and decreased regulatory T-cells, compared to Dom mice. Therapeutic intervention in adult Sub mice treated with HA, celecoxib, or both agents, rescued Sub mice phenotypes. HA treatment reduced Sub mouse gut permeability, increased colon length, and improved mouse social behavior deficits. Treatment with celecoxib increased sociability, reduced depressive- and anxiety-like behaviors, and increased colon length, and a combined treatment resulted in similar effects as celecoxib administered as a single agent. Overall, our data suggest that treating colon inflammation and decreasing gut permeability can restore gut physiology and prevent social deficits later in life. These findings provide critical insights into the importance of early life gut microbiota in shaping gut immunity, functionality, and social behavior, and may be beneficial for the development of future therapeutic strategies.

Sections du résumé

BACKGROUND BACKGROUND
The exact mechanisms linking the gut microbiota and social behavior are still under investigation. We aimed to explore the role of the gut microbiota in shaping social behavior deficits using selectively bred mice possessing dominant (Dom) or submissive (Sub) behavior features. Sub mice exhibit asocial, depressive- and anxiety-like behaviors, as well as systemic inflammation, all of which are shaped by their impaired gut microbiota composition.
METHODS METHODS
An age-dependent comparative analysis of the gut microbiota composition of Dom and Sub mice was performed using 16S rRNA sequencing, from early infancy to adulthood. Dom and Sub gastrointestinal (GI) tract anatomy, function, and immune profiling analyses were performed using histology, RT-PCR, flow cytometry, cytokine array, and dextran-FITC permeability assays. Short chain fatty acids (SCFA) levels in the colons of Dom and Sub mice were quantified using targeted metabolomics. To support our findings, adult Sub mice were orally treated with hyaluronic acid (HA) (30 mg/kg) or with the non-steroidal anti-inflammatory agent celecoxib (16 mg/kg).
RESULTS RESULTS
We demonstrate that from early infancy the Sub mouse gut microbiota lacks essential bacteria for immune maturation, including Lactobacillus and Bifidobacterium genera. Furthermore, from birth, Sub mice possess a thicker colon mucin layer, and from early adulthood, they exhibit shorter colonic length, altered colon integrity with increased gut permeability, reduced SCFA levels and decreased regulatory T-cells, compared to Dom mice. Therapeutic intervention in adult Sub mice treated with HA, celecoxib, or both agents, rescued Sub mice phenotypes. HA treatment reduced Sub mouse gut permeability, increased colon length, and improved mouse social behavior deficits. Treatment with celecoxib increased sociability, reduced depressive- and anxiety-like behaviors, and increased colon length, and a combined treatment resulted in similar effects as celecoxib administered as a single agent.
CONCLUSIONS CONCLUSIONS
Overall, our data suggest that treating colon inflammation and decreasing gut permeability can restore gut physiology and prevent social deficits later in life. These findings provide critical insights into the importance of early life gut microbiota in shaping gut immunity, functionality, and social behavior, and may be beneficial for the development of future therapeutic strategies.

Identifiants

pubmed: 38685001
doi: 10.1186/s12916-024-03323-0
pii: 10.1186/s12916-024-03323-0
doi:

Substances chimiques

Celecoxib JCX84Q7J1L
Hyaluronic Acid 9004-61-9
RNA, Ribosomal, 16S 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

182

Subventions

Organisme : Israel Science Foundation
ID : 2069/17
Organisme : Israel Science Foundation
ID : 1384/18

Informations de copyright

© 2024. The Author(s).

Références

Sci Rep. 2018 Jun 25;8(1):9595
pubmed: 29941995
J Neurochem. 2012 Nov;123(4):555-67
pubmed: 22924711
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Nov 3;71:76-82
pubmed: 27346743
NPJ Biofilms Microbiomes. 2021 Mar 19;7(1):28
pubmed: 33741982
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Microbiome. 2018 May 17;6(1):90
pubmed: 29773078
Psychol Bull. 1995 May;117(3):497-529
pubmed: 7777651
Behav Brain Res. 2016 Feb 1;298(Pt B):25-34
pubmed: 26522843
Cell. 2023 Jun 22;186(13):2823-2838.e20
pubmed: 37236193
Neurobiol Stress. 2020 Mar 20;12:100216
pubmed: 32258258
Cell. 2016 Jun 16;165(7):1762-1775
pubmed: 27315483
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16050-5
pubmed: 21876150
Gastroenterology. 1993 Dec;105(6):1643-50
pubmed: 8253341
Immunity. 2011 May 27;34(5):794-806
pubmed: 21596591
Am J Psychiatry. 2006 Sep;163(9):1630-3
pubmed: 16946190
Mol Psychiatry. 2014 Feb;19(2):146-8
pubmed: 23689536
Eur J Immunol. 2006 Sep;36(9):2336-46
pubmed: 16897813
Neuropsychopharmacology. 2017 Jan;42(1):242-253
pubmed: 27480575
Front Immunol. 2020 Sep 04;11:2054
pubmed: 33013869
Nat Neurosci. 2016 Apr 26;19(6):647-655
pubmed: 29323671
Nucleic Acids Res. 2002 Jul 15;30(14):3059-66
pubmed: 12136088
Nat Mater. 2020 Jan;19(1):118-126
pubmed: 31427744
Int J Inflam. 2010 Oct 03;2010:321426
pubmed: 21152122
Front Behav Neurosci. 2021 Jun 16;15:642757
pubmed: 34220459
Front Psychiatry. 2018 Sep 27;9:454
pubmed: 30319461
Infect Immun. 2018 Nov 20;86(12):
pubmed: 30249750
Behav Brain Res. 2013 Jan 1;236(1):225-235
pubmed: 22982068
Sci Adv. 2020 Oct 14;6(42):
pubmed: 33055169
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Nutrients. 2018 Aug 16;10(8):
pubmed: 30115879
J Psychiatr Res. 2020 Nov;130:48-56
pubmed: 32781373
Front Pharmacol. 2017 Aug 08;8:482
pubmed: 28848431
FEMS Immunol Med Microbiol. 2011 Oct;63(1):129-39
pubmed: 21711398
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
J Affect Disord. 2010 Oct;126(1-2):214-22
pubmed: 20427092
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Exp Med. 1965 Feb 1;121:201-13
pubmed: 14264267
BMC Med. 2017 Jan 11;15(1):7
pubmed: 28073366
Nat Protoc. 2007;2(2):322-8
pubmed: 17406592
Ann Behav Med. 2010 Oct;40(2):218-27
pubmed: 20652462
Am J Physiol Gastrointest Liver Physiol. 2014 Aug 15;307(4):G420-9
pubmed: 24970779
ISME J. 2012 Mar;6(3):610-8
pubmed: 22134646
Gut Microbes. 2012 Jan-Feb;3(1):4-14
pubmed: 22356853
Gut Microbes. 2014 Mar-Apr;5(2):192-201
pubmed: 24637795
Microorganisms. 2022 May 26;10(6):
pubmed: 35744623
PLoS One. 2012;7(7):e42054
pubmed: 22860054
Neuroimmunomodulation. 2013;20(1):39-50
pubmed: 23172104
Microb Ecol Health Dis. 2015 May 29;26:27663
pubmed: 26028277
Int J Environ Res Public Health. 2021 Feb 25;18(5):
pubmed: 33668818
Soc Sci Med. 2000 Sep;51(6):843-57
pubmed: 10972429
J Vis Exp. 2012 Jan 29;(59):e3638
pubmed: 22314943
J Psychopharmacol. 2017 Sep;31(9):1149-1165
pubmed: 28653857
Aging (Albany NY). 2019 Nov 9;11(21):9901-9911
pubmed: 31707362
Ann N Y Acad Sci. 2018 Sep;1428(1):5-13
pubmed: 29806109
PLoS One. 2016 Apr 25;11(4):e0152751
pubmed: 27111847
Nat Commun. 2018 Jan 18;9(1):284
pubmed: 29348443
Matrix Biol. 2018 Mar;66:93-109
pubmed: 28978412
Sci Rep. 2019 Mar 1;9(1):3281
pubmed: 30824791
Arch Gen Psychiatry. 2001 May;58(5):445-52
pubmed: 11343523
J Nutr. 2014 Nov;144(11):1787-96
pubmed: 25332478
Int J Biochem Cell Biol. 1998 Jul;30(7):797-801
pubmed: 9722984
Gigascience. 2019 Mar 1;8(3):
pubmed: 30698687
Physiol Behav. 2009 Aug 4;98(1-2):139-46
pubmed: 19414023
J Allergy Clin Immunol. 1996 Apr;97(4):985-90
pubmed: 8655895
Front Microbiol. 2016 Jun 15;7:925
pubmed: 27379055
PLoS One. 2010 Mar 10;5(3):e9490
pubmed: 20224823
Brain Behav Immun. 2010 May;24(4):558-63
pubmed: 20043983
Endocrine. 2018 Sep;61(3):357-371
pubmed: 29721802
Front Immunol. 2014 Sep 05;5:427
pubmed: 25250028
J Fam Psychol. 2019 Dec;33(8):927-937
pubmed: 31414862
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Psychopharmacology (Berl). 1997 Aug;132(4):335-41
pubmed: 9298510
Nature. 2013 Dec 19;504(7480):446-50
pubmed: 24226770
World J Gastroenterol. 2017 Sep 7;23(33):6016-6029
pubmed: 28970718
Science. 2015 Aug 28;349(6251):993-7
pubmed: 26272906
J Vis Exp. 2011 Feb 25;(48):
pubmed: 21403628
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
J Neuroinflammation. 2010 Dec 17;7:93
pubmed: 21167054
Neurobiol Aging. 2015 May;36(5):1938-52
pubmed: 25796132
Front Microbiol. 2018 May 22;9:1037
pubmed: 29872428

Auteurs

Oryan Agranyoni (O)

Department of Molecular Biology and the Dr. Miriam and Sheldon G. School of Medicine, Ariel University, Ariel, Israel.

Debpali Sur (D)

Department of Molecular Biology and the Dr. Miriam and Sheldon G. School of Medicine, Ariel University, Ariel, Israel.

Sivan Amidror (S)

The Goodman Faculty of Life Sciences, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar Ilan University, Ramat Gan, Israel.

Nuphar Shidlovsky (N)

The Goodman Faculty of Life Sciences, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar Ilan University, Ramat Gan, Israel.

Anastasia Bagaev (A)

Department of Molecular Biology and the Dr. Miriam and Sheldon G. School of Medicine, Ariel University, Ariel, Israel.

Nissan Yissachar (N)

The Goodman Faculty of Life Sciences, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar Ilan University, Ramat Gan, Israel.

Albert Pinhasov (A)

Department of Molecular Biology and the Dr. Miriam and Sheldon G. School of Medicine, Ariel University, Ariel, Israel. albertpi@ariel.ac.il.

Shiri Navon-Venezia (S)

Department of Molecular Biology and the Dr. Miriam and Sheldon G. School of Medicine, Ariel University, Ariel, Israel. shirinv@ariel.ac.il.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH